pulmonary infection
Conditions
Interventions
Conventional dose group:Load dose: 100mg, ivgtt
maintenance dose: 50mg, q12h, ivgtt
High dose group:Load dose: 200mg, ivgtt
maintenance dose: 100mg, q12h, ivgtt
Sponsors
Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Subjects use clinically recognized and up-to-date diagnostic criteria, clinically diagnosed by clinical symptoms, signs, laboratory and X-ray examinations for patients with bacterial lung infections who require antimicrobial therapy; (2) According to the standard principle of empirical treatment or pathogen test results, the pathogen is shown in the antibacterial spectrum of tigecycline; (3) The effective antibacterial drug has not been used within 72 hours before the subject is selected, or the antibacterial drug has not been used; (4) Aged at least 18 years old, male and female; (5) The subject has no serious liver, kidney, cardiovascular and hematopoietic diseases; (6) Patients of childbearing age are willing to take appropriate methods of contraception; (7) The subject is an inpatient; (8) Voluntary subjects and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients who are known or suspected to be allergic to tigecycline or tetracycline antibiotics or have serious adverse reactions; (2) Patients who have received any other test medications during the first three months of screening or enrollment; (3) Patients who are being treated with cyclosporine and warfarin; (4) Patients who have been selected for clinical trials of this study drug; (5) Patients with other diseases that the study believes will not be able to evaluate efficacy or are unlikely to complete the expected course of treatment and visits; (6) Patients with severe liver damage (Child Pugh grade C); (7) Women during pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma concentration of tigecycline;bronchoalveolar lavage fluid concentration of tigecycline; | — |
Secondary
| Measure | Time frame |
|---|---|
| serum concentration of urea;bronchoalveolar lavage fluid concentration of urea; | — |
Countries
China
Contacts
Public ContactYang Yong
Sichuan Provincial People's Hospital
Outcome results
None listed